Trastuzumab deruxtecan clinical trials
Also written Enhertu, DS-8201a and DS-8201.
ClinicalTrials.gov finds 231 studies for trastuzumab deruxtecan. How that becomes 120 here
Every study that search finds has been read, to see whether and how it gives trastuzumab deruxtecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 231Found by its intervention search · See all 231 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 152 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −15
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205 · Earlier treatment, not given in this studyReport a problem
- Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 · Earlier treatment, not given in this studyReport a problem
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)NCT06100874 · Earlier treatment, not given in this studyReport a problem
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429 · Earlier treatment, not given in this studyReport a problem
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerNCT06665178 · Earlier treatment, not given in this studyReport a problem
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)NCT06686394 · Patritumab deruxtecan, a different drugReport a problem
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 · Earlier treatment, not given in this studyReport a problem
- RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyNCT07065435 · Earlier treatment, not given in this studyReport a problem
- A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNCT07294534 · Named only to describe new HLX87Report a problem
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNCT07333937 · Earlier treatment, not given in this studyReport a problem
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerNCT07393425 · SHR-A1811, trastuzumab rezetecan, named as trastuzumab deruxtecanReport a problem
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyNCT07446452 · Earlier treatment, not given in this studyReport a problem
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNCT07466303 · Trastuzumab rezetecan, a different drugReport a problem
- Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsNCT07610616 · Tested on lung cancer organoids in the laboratoryReport a problem
- SMP-656 for HER2-Positive Advanced Breast CancerNCT07726342 · Earlier treatment, not given in this studyReport a problem
- +4Give it under a name that search misses: a biosimilar’s code or a misspelling
- 220Give trastuzumab deruxtecan to participants
- −41Observe patients on it, or give it outside a trial
- −1Use it as a tool: an imaging tracer or a test of drug response
- −8Compare another treatment with it
- −50Give it beside what is tested
- 120Test it: the count on this site
Get an email when these change. Save the trastuzumab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Dec 2019 · ENHERTU · BLA 761139 (FDA, Drugs@FDA)
- European Union
- 18 Jan 2021 · Enhertu · EMEA/H/C/005124 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
116 studies that test it; most in 2025 (24); 4 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 2 |
| 2020 | 13 |
| 2021 | 11 |
| 2022 | 5 |
| 2023 | 13 |
| 2024 | 16 |
| 2025 | 24 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 49 · Other 71
AstraZeneca (21) · Daiichi Sankyo (20) · National Cancer Institute (NCI) (7) · Daiichi Sankyo Co., Ltd. (5) · Fudan University (5) · MedSIR (4) · UNICANCER (4) · Yonsei University (4)
Often tested with
Tested in the same studies.
Pertuzumab (5) · Rilvegostomig (5) · Trastuzumab (5) · Capecitabine (5) · Sacituzumab govitecan (5) · Nivolumab (4) · Tucatinib (4) · Olaparib (4)
Related medicines
As reviewed, each with the page that says it.
- A conjugate made from Trastuzumab
- One of Antibody-drug conjugates (ADCs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Trastuzumab deruxtecan is the comparator. A study of two new drugs counts under both.
- 1Apatinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Mar 2031
- 1Patritumab deruxtecan · Merck Sharp & Dohme LLC · next primary completion Jul 2033
New treatments tested with it · 8 most studied
New when their studies opened, with trastuzumab deruxtecan beside them; studies of each.
Reaching primary completion within a year · 28, 2 in phase 3
Studies that test trastuzumab deruxtecan, phase 3 first.
- May 2027Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 3 · AstraZeneca
- Oct 2027Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerPhase 3 · Daiichi Sankyo
- Nov 2026T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesPhase 2 · MedSIR
- Dec 2026Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesPhase 2 · Yonsei University
- Dec 2026Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor TherapyPhase 2 · Yonsei University
- Dec 2026Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerPhase 1 · National Cancer Institute (NCI)
- Dec 2026Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Jan 2027Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypePhase 2 · MedSIR
- Jan 2027Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesPhase 1/2 · Fudan University
- Feb 2027A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsPhase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses trastuzumab deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 120
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112With rilvegostomig or pembrolizumab (DESTINY-Endometrial01)Written as Trastuzumab deruxtecanReport a problem
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNot yet recruitingPhase 2Centre Leon BerardNCT07936422Alone in a HER2 cohort of a platform trialWritten as Trastuzumab Deruxtecan for Injection (T-DXd)Report a problem
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingPhase 2National Cancer Institute (NCI)NCT04616560In osteosarcoma and other children's tumoursWritten as Trastuzumab DeruxtecanReport a problem
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614With neratinib in HER2-altered cancersWritten as Trastuzumab DeruxtecanReport a problem
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958With olaparib in HER2-expressing cancersWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Added to rilvegostomig and chemotherapy in one sub-studyWritten as Trastuzumab Deruxtecan (T-DXd)Report a problem
- Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07619365With lovastatin in HER2-low and ultralow breast cancerWritten as Trastuzumab deruxtecanReport a problem
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Not yet recruitingPhase 2Azienda Ospedaliero-Universitaria CareggiNCT07905313With radiosurgery for brain metastasesWritten as SRS/fSRT+T-DxdReport a problem
- Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyRecruitingPhase 2UNICANCERNCT06680596After persistent ctDNA on a CDK4/6 inhibitorReport a problem
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingPhase 3Daiichi SankyoNCT06819007With bevacizumab against bevacizumab maintenance in ovarian cancerWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingRecruitingPhase 3Daiichi SankyoNCT07022483Adjuvant against chemotherapy in endometrial cancerWritten as Trastuzumab DeruxtecanReport a problem
- A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingPhase 3Daiichi SankyoNCT06174987Continued for people from earlier studiesWritten as T-DXdReport a problem
- Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingPhase 1/2Fudan UniversityNCT07134153Into the spinal fluid for leptomeningeal metastasesWritten as T-DXdReport a problem
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06899126With pembrolizumab against chemotherapy in lung cancer (DESTINY-Lung06)Written as Trastuzumab DeruxtecanReport a problem
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Against docetaxel and trastuzumab, as is T-DM1Written as Trastuzumab DeruxtecanReport a problem
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT07619521With selumetinib in pancreatic cancerWritten as Trastuzumab DeruxtecanReport a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214One biomarker-directed ADC (ADC MATCH)Written as Trastuzumab DeruxtecanReport a problem
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875With rilvegostomig and chemotherapy against trastuzumab regimensWritten as Trastuzumab deruxtecanReport a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754With pertuzumab, then endocrine therapy and dual HER2 blockadeWritten as Trastuzumab deruxtecanReport a problem
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389One targeted option matched to the tumourWritten as Trastuzumab deruxtecanReport a problem
See all 120 studies that test trastuzumab deruxtecan →
Behind its US label · 13 — the studies the FDA label of ENHERTU describes
From the Clinical Studies section of ENHERTU (2026-05), as openFDA has it. A study the site does not hold is left out.
- A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedPhase 2Daiichi SankyoNCT03248492Report a problem
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]CompletedPhase 2Daiichi Sankyo Co., Ltd.NCT03329690Report a problem
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedPhase 2Daiichi SankyoNCT03505710Report a problem
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedPhase 3Daiichi SankyoNCT03523585Report a problem
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedPhase 3Daiichi SankyoNCT03529110Report a problem
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedPhase 3Daiichi SankyoNCT03734029Report a problem
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsActive, not recruitingPhase 2AstraZenecaNCT04482309Report a problem
- Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerActive, not recruitingPhase 3AstraZenecaNCT04494425Report a problem
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingPhase 3Daiichi SankyoNCT04622319Report a problem
- Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2Daiichi SankyoNCT04644237Report a problem
- Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal CancerCompletedPhase 2Daiichi SankyoNCT04744831Report a problem
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active, not recruitingPhase 3AstraZenecaNCT04784715Report a problem
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingPhase 3AstraZenecaNCT05113251Report a problem
Tested on its own · 52 — no other medicine in its arm
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNot yet recruitingPhase 2Centre Leon BerardNCT07936422Alone in a HER2 cohort of a platform trialWritten as Trastuzumab Deruxtecan for Injection (T-DXd)Report a problem
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingPhase 2National Cancer Institute (NCI)NCT04616560In osteosarcoma and other children's tumoursWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingRecruitingPhase 3Daiichi SankyoNCT07022483Adjuvant against chemotherapy in endometrial cancerWritten as Trastuzumab DeruxtecanReport a problem
- A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingPhase 3Daiichi SankyoNCT06174987Continued for people from earlier studiesWritten as T-DXdReport a problem
- Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingPhase 1/2Fudan UniversityNCT07134153Into the spinal fluid for leptomeningeal metastasesWritten as T-DXdReport a problem
- Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.RecruitingPhase 4Institut Claudius RegaudNCT07195344Payload exposure and toxicity by patient characteristicsReport a problem
- Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNot yet recruitingPhase 1Baptist Health South FloridaNCT07454668With radiosurgery for brain metastasesWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07691489With cetuximab in colorectal cancerWritten as Fam-Trastuzumab Deruxtecan-NxkiReport a problem
- Trial of Trastuzumab Deruxtecan in Previously Treated HER2RecruitingPhase 2Yale UniversityNCT06750484Alone in HER2-0 breast cancer after treatmentWritten as Trastuzumab DeruxtecanReport a problem
- A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerNot yet recruitingNot applicableShuangyue LiuNCT07782086In AI-assessed HER2-ultralow breast cancerWritten as Trastuzumab Deruxtecan (T-DXd, ENHERTU®)Report a problem
- A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsRecruitingPhase 1Daiichi SankyoNCT07015697Under the skin, doses foundWritten as Trastuzumab DeruxtecanReport a problem
- Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingPhase 3Daiichi SankyoNCT05950945By hormone receptor and HER2 level (DESTINY-Breast15)Written as Trastuzumab DeruxtecanReport a problem
- Castrate Resistant Prostate Cancer Enhertu TherapyRecruitingPhase 2Washington D.C. Veterans Affairs Medical CenterNCT06610825In HER2-positive prostate cancerWritten as EnhertuReport a problem
- Trastuzumab Deruxtecan (T-DXd) for People With Brain CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06058988Tumour penetration in brain cancerWritten as Trastuzumab deruxtecanReport a problem
- Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationPhase 2Yonsei UniversityNCT06250777In HER2-mutant lung cancer with brain metastasesWritten as Trastuzumab deruxtecanReport a problem
- Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI CancersNot yet recruitingPhase 2University of ChicagoNCT07126561In newly diagnosed metastatic GI cancersWritten as Trastuzumab DeruxtecanReport a problem
- Basket Study for Oligo-metastatic Breast CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT05982678Around local treatment in oligometastatic breast cancerWritten as Trastuzumab deruxtecanReport a problem
- A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingPhase 3Prof. Wolfgang JanniNCT06643585Against standard care as secondary adjuvantWritten as Trastuzumab-DeruxtecanReport a problem
- Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal CancerRecruitingPhase 2University of SouthamptonNCT05965479Adjuvant, guided by ctDNA, in gastro-oesophageal cancerWritten as Trastuzumab deruxtecanReport a problem
- T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06548178Against THP before breast surgeryWritten as T-DXdReport a problem
Showing 20 of 52. See all 52 →
Tested with established drugs · 16 — they are given beside it
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Not yet recruitingPhase 2Azienda Ospedaliero-Universitaria CareggiNCT07905313With radiosurgery for brain metastasesWritten as SRS/fSRT+T-DxdReport a problem
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)RecruitingPhase 3Daiichi SankyoNCT06819007With bevacizumab against bevacizumab maintenance in ovarian cancerWritten as Trastuzumab DeruxtecanReport a problem
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingPhase 3Daiichi SankyoNCT06899126With pembrolizumab against chemotherapy in lung cancer (DESTINY-Lung06)Written as Trastuzumab DeruxtecanReport a problem
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingPhase 3Daiichi SankyoNCT06731478With chemotherapy and pembrolizumab against trastuzumab (DESTINY-Gastric05)Written as Trastuzumab DeruxtecanReport a problem
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingPhase 2UNICANCERNCT07151586Alternated with sacituzumab govitecan against it aloneWritten as Sacituzumab Govitecan / Trastuzumab DeruxtecanReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883Against CDK4/6 inhibitor with endocrine therapy, first-lineWritten as Trastuzumab deruxtecan (T-DXd, DS-8201a)Report a problem
- Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor TherapyRecruitingPhase 2Yonsei UniversityNCT07340164Against platinum chemotherapy after a PARP inhibitorWritten as Trastzumab DeruxtecanReport a problem
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingPhase 1AstraZenecaNCT04686305With immunotherapy and chemotherapy in lung cancer (DESTINY-Lung03)Written as T-DXdReport a problem
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT07371585With pertuzumab and proactive toxicity management, first-lineWritten as T-DXdReport a problem
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Against TCHP or PCHP before breast surgeryWritten as Trastuzumab deruxtecanReport a problem
- A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsActive, not recruitingPhase 2AstraZenecaNCT06271837Alone or with bevacizumab in HER2-expressing tumoursWritten as Trastuzumab deruxtecanReport a problem
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingPhase 1AstraZenecaNCT04556773Combinations in HER2-low breast cancer (DESTINY-Breast08)Written as Trastuzumab deruxtecanReport a problem
- Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal CancerCompletedPhase 2Daiichi SankyoNCT04744831On the US labelTwo doses in colorectal cancer (DESTINY-CRC02)Written as DS-8201a 5.4 mg/kg Q3WReport a problem
- DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingPhase 1Daiichi SankyoNCT04042701With pembrolizumab in breast and lung cancerWritten as Trastuzumab deruxtecan (DS-8201a)Report a problem
- Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedPhase 1Daiichi SankyoNCT03523572With nivolumab in breast and bladder cancerWritten as Trastuzumab deruxtecanReport a problem
- Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT03383692Interaction with ritonavir and itraconazoleWritten as DS-8201aReport a problem
Tested in a combination · 52 — another drug in the study is under test too
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112With rilvegostomig or pembrolizumab (DESTINY-Endometrial01)Written as Trastuzumab deruxtecanReport a problem
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614With neratinib in HER2-altered cancersWritten as Trastuzumab DeruxtecanReport a problem
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958With olaparib in HER2-expressing cancersWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Added to rilvegostomig and chemotherapy in one sub-studyWritten as Trastuzumab Deruxtecan (T-DXd)Report a problem
- Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07619365With lovastatin in HER2-low and ultralow breast cancerWritten as Trastuzumab deruxtecanReport a problem
- Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyRecruitingPhase 2UNICANCERNCT06680596After persistent ctDNA on a CDK4/6 inhibitorReport a problem
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Against docetaxel and trastuzumab, as is T-DM1Written as Trastuzumab DeruxtecanReport a problem
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT07619521With selumetinib in pancreatic cancerWritten as Trastuzumab DeruxtecanReport a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214One biomarker-directed ADC (ADC MATCH)Written as Trastuzumab DeruxtecanReport a problem
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875With rilvegostomig and chemotherapy against trastuzumab regimensWritten as Trastuzumab deruxtecanReport a problem
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754With pertuzumab, then endocrine therapy and dual HER2 blockadeWritten as Trastuzumab deruxtecanReport a problem
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389One targeted option matched to the tumourWritten as Trastuzumab deruxtecanReport a problem
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357With or without rilvegostomig against standard care (DESTINY-BTC01)Written as Trastuzumab deruxtecanReport a problem
- TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingPhase 2Filipa Lynce, MDNCT05795101With durvalumab in inflammatory breast cancerWritten as Trastuzumab deruxtecanReport a problem
- Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual DiseaseRecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT06253650Adjuvant with fluoropyrimidine against chemotherapyReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug matched to tumour geneticsWritten as Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Report a problem
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer PatientsRecruitingPhase 1Fox Chase Cancer CenterNCT05274048With neratinib in gastro-oesophageal cancerWritten as Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Report a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753One protein-matched ADCWritten as Trastuzumab deruxtecan (T-DXd)Report a problem
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450One matched cohort before colorectal surgeryWritten as Trastuzumab deruxtecanReport a problem
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingPhase 1/2National Cancer Institute (NCI)NCT07012031With sotorasib in lung cancerWritten as Trastuzumab DeruxtecanReport a problem
Showing 20 of 52. See all 52 →
Beside an established treatment under test · 4 — an approved drug, surgery or radiation is what the study tests
Tested with trastuzumab deruxtecan: HER2-targeted Therapy 1 · Trastuzumab 1 · Surgery or a procedure 1 · Radiation 1 · neratinib 1 · Bevacizumab 1 · Hydroxychloroquine 1
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingPhase 3SWOG Cancer Research NetworkNCT07578116One systemic option; surgery and radiation are addedWritten as Trastuzumab DeruxtecanReport a problem
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07152782In every armBoth arms take it while neratinib is addedWritten as Trastuzumab DeruxtecanReport a problem
- T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07150208In every armBoth arms take it while bevacizumab is addedWritten as Trastuzumab Deruxtecan (T-DXd)Report a problem
- HCQ+ADC vs ADC in the Treatment of Advanced Breast CancerRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06328387Both its arms take it while hydroxychloroquine is addedWritten as Trastuzumab DeruxtecanReport a problem
Beside a new treatment under test · 33 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with trastuzumab deruxtecan: ivonescimab 3 · SGN-LIV1A 2 · zanidatamab 2 · dulpatatug 2 · ceralasertib 1 · AZD5305 1 · valemetostat 1 · SIRP-alpha-Fc Fusion Protein HCB101 1
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Partner of new zongertinibWritten as Trastuzumab deruxtecanReport a problem
- EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsRecruitingPhase 1/2Eisbach Bio GmbHNCT06525298Partner of new EIS-12656 in one moduleWritten as Trastuzumab deruxtecanReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Partner of new inavolisib in two platform armsWritten as Trastuzumab DeruxtecanReport a problem
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingPhase 1Eli Lilly and CompanyNCT05614739Partner of new vepugratinibWritten as Trastuzumab DeruxtecanReport a problem
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT06364410In every armPartner of new azenosertibWritten as Trastuzumab DeruxtecanReport a problem
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1Daiichi SankyoNCT05765851In every armPartner of new DS-1103aWritten as T-DXdReport a problem
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT07137416In every armPartner of new pidnarulexWritten as Trastuzumab DeruxtecanReport a problem
- Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1Lei ZhengNCT07086768Partner of new BSI-082 in one cohortReport a problem
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05417594Partner of new AZD9574 in one moduleWritten as Trastuzumab Deruxtecan (T-DXd)Report a problem
- A Study of PHST001 in Advanced Solid TumorsRecruitingPhase 1Pheast TherapeuticsNCT06840886Partner of new PHST001 in one cohortWritten as Trastuzumab DeruxtecanReport a problem
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Daiichi SankyoNCT07701941In every armEvery arm takes it while new HER3-DXd is addedWritten as Trastuzumab deruxtecanReport a problem
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Partner of new evorpaceptWritten as Fam-Trastuzumab Deruxtecan-NxkiReport a problem
- A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingPhase 2Fujian Medical UniversityNCT07836257In every armContinued while pyrotinib is added after progressionWritten as Trastuzumab Deruxtecan (T-DXd)Report a problem
- Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerNot yet recruitingPhase 1/2The Methodist Hospital Research InstituteNCT07785856In every armPartner of new azeliragon after T-DXd resistanceWritten as T-DXdReport a problem
- Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast CancersRecruitingPhase 1M.D. Anderson Cancer CenterNCT07553390In every armPartner of new TRICK-NK cellsWritten as Trastuzumab deruxtecan (T-DXd)Report a problem
- Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer StudyRecruitingPhase 2Fudan UniversityNCT07647016In every armPartner of ivonescimab, approved only in ChinaWritten as Trastuzumab Deruxtecan and ivonescimabReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Partner of new rilvegostomig in one I-SPY armReport a problem
- A Study of DB-1310 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05785741Partner of new DB-1310 in one cohortReport a problem
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07294508With pertuzumab in the comparator arm for new HLX87Written as T-Dxd + PertuzumabReport a problem
- ctDNA-guided Treatment Decision-makingRecruitingPhase 2Fudan UniversityNCT07394218One ADC option; ivonescimab is added by ctDNAReport a problem
Showing 20 of 33. See all 33 →
Beside supportive care · 13 — a supportive treatment or test is studied
- SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesRecruitingPhase 2Jules Bordet InstituteNCT07474558One ADC background; scalp cooling against hair loss is testedReport a problem
- Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab DeruxtecanNot yet recruitingPhase 3Mario Negri Institute for Pharmacological ResearchNCT07828054In every armBackground; dexamethasone against lung disease is testedWritten as T-DXdReport a problem
- GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast CancerNot yet recruitingNot applicableBreast Cancer Trials, Australia and New ZealandNCT07465172Treatment whose side effects a blood marker tracksReport a problem
- Megestrol Acetate for Fatigue Management in T-DXd Treated Breast CancerRecruitingPhase 3Sun Yat-sen UniversityNCT07543536Background; megestrol against its fatigue is testedWritten as Megestrol Acetate + Trastuzumab DeruxtecanReport a problem
- Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.Not yet recruitingPhase 2UNICANCERNCT07294430Treatment whose response antibody PET predictsReport a problem
- Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07716189Background; ear stimulation against its nausea is testedReport a problem
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisRecruitingPhase 4City of Hope Medical CenterNCT05376878In every armTreatment the investigational trastuzumab PET scan followsWritten as Trastuzumab DeruxtecanReport a problem
- Scalp Cooling in MBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04986579Background treatment; scalp cooling against hair loss is testedWritten as Trastuzumab deruxtecanReport a problem
- Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07537673Background; ear stimulation and dexamethasone against its nauseaReport a problem
- Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersRecruitingPhase 2UNICANCERNCT07259226Standard treatment during which resistance markers are studiedReport a problem
- PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast CancerNot yet recruitingNot applicableCentre Paul StraussNCT07130344Treatment whose response PET evaluatesReport a problem
- Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06797622In every armTreatment whose response a FAPI PET scan predictsWritten as Trastuzumab deruxtecan (T-DXd)Report a problem
- Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid BiopsyRecruitingNot applicableFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT05919212Standard second-line treatment; liquid biopsy tracks resistanceReport a problem
As the comparator · 8 — what is tested is compared with trastuzumab deruxtecan
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807One physician's-choice option against patritumab deruxtecanWritten as Trastuzumab deruxtecanReport a problem
- A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07678957Comparator for new BL-M07D1Written as DS-8201Report a problem
- Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07630103Comparator for new trastuzumab rezetecanWritten as Trastuzumab Deruxtecan for Injection (T-DXd)Report a problem
- A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07497386Comparator for new trastuzumab rezetecan dosesWritten as Trastuzumab Deruxtecan for InjectionReport a problem
- Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07416253Comparator for new trastuzumab rezetecan before surgeryWritten as Trastuzumab deruxtecanReport a problem
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07417241Later treatment in the comparator arm against new SHR-A1811Written as T-DXdReport a problem
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824One physician's-choice option against organoid-guided treatmentWritten as Trastuzumab deruxtecanReport a problem
- Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast CancerActive, not recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07371910One physician's-choice option against fluzoparib and apatinibReport a problem
Observed · 41 — patients on it are followed, or it is given outside a trial
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingHellenic Cooperative Oncology GroupNCT07066917Among ADCs, response and resistance studiedReport a problem
- DESTINY-PANTUMOUR04RecruitingAstraZenecaNCT07124000Real-world use in HER2-positive solid tumours (DESTINY-PanTumour04)Written as Trastuzumab deruxtecanReport a problem
- BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyRecruitingAstraZenecaNCT07597993Real-world use in HR-positive HER2-low breast cancerReport a problem
- Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerRecruitingAstraZenecaNCT06727227Real-world use in HER2-low breast cancerWritten as trastuzumab deruxtecanReport a problem
- PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanRecruitingAstraZenecaNCT05573893Patient-reported outcomes in HER2-low breast cancerReport a problem
- DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNCT05945732Real-world use in HER2-low breast cancer in EuropeWritten as Trastuzumab deruxtecanReport a problem
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingDaiichi SankyoNCT06846996Real-world use in gastric cancerWritten as Trastuzumab deruxtecan (T-DXd)Report a problem
- Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingDaiichi SankyoNCT06809764Real-world use in Chinese HER2-mutant lung cancerReport a problem
- A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast CancerRecruitingFudan UniversityNCT07653893Spinal fluid levels and efficacyReport a problem
- Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsRecruitingSun Yat-sen UniversityNCT06551220Benefit by HER2 heterogeneityWritten as Trastuzumab DeruxtecanReport a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingFundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalNCT07582887Genetic variants and ADC toxicityWritten as Trastuzumab deruxtecanReport a problem
- Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in KoreaRecruitingSeoul National University HospitalNCT06928818T-DM1 right after it observedReport a problem
- Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4RecruitingNot applicableInstitut CurieNCT05088395ctDNA during treatment, in one cohortReport a problem
- A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingDaiichi SankyoNCT06210776Real-world use in Chinese breast cancer (REFRESH)Written as Trastuzumab deruxtecanReport a problem
- Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast CancerRecruitingEuropean Institute of OncologyNCT07049133Markers of its toxicityReport a problem
- A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer PatientsRecruitingNot applicableBlokhin's Russian Cancer Research CenterNCT07281001Retrospective real-world use in RussiaWritten as T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.Report a problem
- HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBCRecruitingRenske AltenaNCT06830382HER2-PET in patients starting itReport a problem
- Trastuzumab Deruxtecan in Advanced Breast CancerRecruitingWenjin YinNCT07180264Real-world use in advanced breast cancerWritten as Trastuzumab deruxtecanReport a problem
- Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdRecruitingHunan Cancer HospitalNCT07073755Later treatment after resistance to itReport a problem
- A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast CancerNot yet recruitingTianjin Medical University Cancer Institute and HospitalNCT07035353Real-world use in Chinese breast cancerWritten as T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.Report a problem
Showing 20 of 41. See all 41 →
As a tool · 1 — an imaging tracer or a test of drug response
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Results posted1
- Testing the Biological Effects of DS-8201a on Patients With Advanced CancerNov 17, 2026NCT04294628
Stopped1
- A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerWithdrawnOct 20, 2026NCT07428044
Newly registered2
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNov 13, 2026NCT07936422
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Oct 29, 2026NCT07905313
Codes
What other systems call trastuzumab deruxtecan · ClinicalTrials.gg INT000605
- MeSH (NLM) C000614160trastuzumab deruxtecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5384HK7574TRASTUZUMAB DERUXTECANConfirmed FDA, NLM, Wikidata
- RxNorm 2267582One source FDA
- Wikidata Q80109553trastuzumab deruxtecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C128799Trastuzumab DeruxtecanOne source FDA
- DrugBank DB14962One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614160 | trastuzumab deruxtecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5384HK7574 | TRASTUZUMAB DERUXTECAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2267582 | — | One source FDA |
| Wikidata | Q80109553 | trastuzumab deruxtecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C128799 | Trastuzumab Deruxtecan | One source FDA |
| DrugBank | DB14962 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.